Macrolides in cystic fibrosis

Chronic Respiratory Disease

Volumn 2, Issue 2, 2005, Pages 85-98

  Bell, Scott C ^a,b   Senini, S L ^b   McCormack, J G ^b  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Azithromycin; Cystic fibrosis; Diffuse pan bronchiolitis; Inflammation; Macrolides

Indexed keywords

AZITHROMYCIN; CARBAMAZEPINE; CLARITHROMYCIN; CYTOKINE; DIGOXIN; DIRITHROMYCIN; ERYTHROMYCIN; FLURITHROMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; JOSAMYCIN; MACROLIDE; MIDECAMYCIN; MIOKAMYCIN; OMEPRAZOLE; PLACEBO; RIFABUTIN; RIFAMPICIN; ROKITAMYCIN; ROSARAMICIN; ROXITHROMYCIN; SPIRAMYCIN; STEROID; TERFENADINE; THEOPHYLLINE; TROLEANDOMYCIN; TYLOSIN; WARFARIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHIOLITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; CYSTIC FIBROSIS; CYTOKINE RELEASE; DIARRHEA; DRUG EFFECT; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG PENETRATION; DRUG STRUCTURE; DRUG TOLERABILITY; EDEMA; HISTORY OF MEDICINE; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INFLAMMATION; LICENSING; LUNG FUNCTION; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CYSTIC FIBROSIS; HUMANS; MACROLIDES;

EID: 14844323083     PISSN: 14799723     EISSN: 14799731     Source Type: Journal    
DOI: 10.1191/1479972305cd066rs     Document Type: Review

References (102)

1. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57: 212-16.
2. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002; 360: 978-84.
3. Saiman L, Marshall BC, Mayer-Hamblett N et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290: 1749-56.
4. McGuire JM, Buch RL, Anderson A et al. 'Itotycin', a new antibiotic. Antibiot Chemother 1952; 28: 281.
5. Kirst HA. New macrolides: expanded horizons for an old class of antibiotics. J Antimicrob Chemother 1991; 28: 787-90.
6. Itkin IH, Menzel ML. The use of macrolide antibiotic substances in the treatment of asthma. J Allergy 1970; 45: 146-62.
7. Cazzola M, Salzillo A, Diamare F. Potential role of macrolides in the treatment of asthma. Monaldi Archives for Chest Disease 2000; 55: 231-63.
8. Zeiger RS, Schatz M, Sperling W, Simon RA, Stevenson DD. Efficacy of troleandomycin in outpatients with severe, corticosteroid-dependent asthma. J Allergy Clin Immunol 1980; 66: 438-46.
9. Miyatake H, Taki F, Taniguchi H, Suzuki R, Takagi K, Satake T. Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Chest 1991; 99: 670-73.
10. Kamoi H, Kurihara N, Fujiwara H, Hirata K, Takeda T. The macrolide antibacterial roxithromycin reduces bronchial hyperresponsiveness and Superoxide anion production by polymorphonuclear leukocytes in patients with asthma. J Asthma 1995; 32: 191-97.
11. Kostadima E, Tsiodras S, Alexopoulos EI et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. European Respiratory Journal 2004; 23: 714-17.
12. Kudoh S, Uetake T, Hagiwara K et al. Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi 1987; 25: 632-42.
13. Amsden GW. Erythromycin, clarithromycin, and azithromycin: are the differences real? Clin Ther 1996; 18: 56-72.
14. Scaglione F, Rossoni G. Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J Antimicrob Chemother 1998; 41(Suppl B): 47-50.
15. Carbon C. Clinical relevance of intracellular and extracellular concentrations of macrolides. Infection 1995; 23(Suppl 1): S10-14.
16. Wales D, Woodhead M. The anti-inflammatory effects of macrolides. Thorax 1999; 54(Suppl 2): S58-62.
17. Snow V, Mottur-Pilson C, Gonzales R. Principles of appropriate antibiotic use for treatment of acute bronchitis in adults. Ann Intern Med 2001; 134: 518-20.
18. Snow V, Mottur-Pilson C, Cooper RJ, Huffman JR. Principles of appropriate antibiotic use for acute pharyngitis in adults. Ann Intern Med 2001; 134: 506-508.
19. Kucers A, Crowe SM, Grayson ML, Hoy JF. The use of antibiotics. A clinical review of antibacterial, anifungal and antiviral drugs. Fifth edition. Oxford: Butterworth Heinemann, 1997: 606-52.
20. Albrich WC, Monnet DL, Harbarth S. Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Emerg Infect Dis 2004; 10: 514-17.
21. Turnidge JD, Bell JM, Collignon PJ. Rapidly emerging antimicrobial resistances in Streptococcus pneumoniae in Australia. Pneumococcal Study Group. Med J Aust 1999; 170: 152-55.
22. Eady EA, Holland KT, Cunliffe WJ. The use of antibiotics in acne therapy: oral or topical administration? J Antimicrob Chemother 1982; 10: 89-115.
23. Dalziel K, Dykes PJ, Marks R. The effect of tetracycline and erythromycin in a model of acne-type inflammation. Br J Exp Pathol 1987; 68: 67-70.
24. Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001; 31: 464-73.
25. Labro MT. Anti-inflammatory activity of macrolides: a new therapeutic potential? J Antimicrobial Chemother 1998; 41(Suppl B): 37-46.
26. Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429: 209-29.
27. Tamaoki J. The effects of macrolides on inflammatory cells. Chest 2004; 125(Suppl 2): 41S-50S.
28. Brown RK, Wyatt H, Price JF, Kelly FJ. Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress. Eur Respir J 1996; 9: 334-39.
29. Abdelghaffar H, Soukri A, Babin Chevaye C, Labro MT. Interaction of macrolides and ketolides with the phagocytic cell line PLB-985. Journal of Chemotherapy Florence, Italy 2003; 15: 350-56.
30. Hoyt JC, Robbins RA. Macrolide antibiotics and pulmonary inflammation. FEMS Microbiol Lett 2001; 205: 1-7.
31. Anderson R. Erythromycin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant-activated superoxide generation and autooxidation. J Infect Dis 1989; 159: 966-73.
32. Hand WL, Hand DL, King-Thompson NL. Antibiotic inhibition of the respiratory burst response in human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1990; 34: 863-70.
33. Culic O, Erakovic V, Cepelak I et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 2002; 450: 277-89.
34. Gorrini M, Lupi A, Viglio S et al. Inhibition of human neutrophil elastase by erythromycin and flurythromycin, two macrolide antibiotics. Am J Respir Cell Mol Biol 2001; 25: 492-99.
35. Abdelghaffar H, Vazifeh D, Labro MT. Comparison of various macrolides on stimulation of human neutrophil degranulation in vitro. J Antimicrobial Chemother 1996; 38: 81-93.
36. Takeshita K, Yamagishi I, Harada M, Otomo S, Nakagawa T, Mizushima Y. Immunological and anti-inflammatory effects of clarithromycin: inhibition of interleukin 1 production of murine peritoneal macrophages. Drugs Exp Clin Res 1989; 15: 527-33.
37. Morikawa K, Oseko F, Morikawa S, Iwamoto K. Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. Antimicrob Agents Chemother 1994; 38: 2643-47.
38. Sakito O, Kadota J, Kohno S, Abe K, Shirai R, Hara K. Interleukin l beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996; 63: 42-48.
39. Takizawa H, Desaki M, Ohtoshi T et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 1997; 156: 266-71.
40. Kohyama T, Takizawa H, Kawasaki S, Akiyama N, Sato M, Ito K. Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. Antimicrob Agents Chemother 1999; 43: 907-11.
41. Baggiolini M, Clark-Lewis I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett 1992; 307: 97-101.
42. Kunkel SL, Standiford T, Kasahara K, Stricter RM. Interleukin-8 (IL-8): the major neutrophil chemotactic factor in the lung. Exp Lung Res 1991; 17: 17-23.
43. Khair OA, Devalia JL, Abdelaziz MM, Sapsford RJ, Davies RJ. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Eur Respir J 1995; 8: 1451-57.
44. Kawasaki S, Takizawa H, Ohtoshi T et al. Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro. Antimicrob Agents Chemother 1998; 42: 1499-502.
45. Aoki Y, Kao PN. Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells. Antimicrob Agents Chemother 1999; 43: 2678-84.
46. Ichiyama T, Nishikawa M, Yoshitomi T et al. Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob Agents Chemother 2001; 45: 44-47.
47. Wang L, Kitaichi K, Hui CS et al. Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo. Clin Exp Pharmacol Physiol 2000; 27: 587-93.
48. Mikasa K, Sawaki M, Kita E et al. Significant survival benefit to patients with advanced non-small-cell lung cancer from treatment with Clarithromycin. Chemotherapy 1997; 43: 288-96.
49. Saikku P, Leinonen M, Manila K et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983-86.
50. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-407.
51. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet 1997; 350: 404-407.
52. O'Connor CM, Dunne MW, Pfeffer MA et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 2003; 290: 1459-66.
53. Banerjee D, Honeybourne D, Khair OA. The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial. [Clinical trial. Journal article. Randomized controlled trial] Treatments in Respiratory Medicine 2004; 3: 59-65.
54. Iino Y, Sugita K, Toriyama M, Kudo K. Erythromycin therapy for otitis media with effusion in sinobronchial syndrome. Arch Otolaryngol Head Neck Surg 1993; 119: 648-51.
55. Hashiba M, Baba S. Efficacy of long-term administration of clarithromycin in the treatment of intractable chronic sinusitis. Acta Otolaryngol Suppl 1996; 525: 73-78.
56. Suzuki H, Shimomura A, Ikeda K, Oshima T, Takasaka T. Effects of long-term low-dose macrolide administration on neutrophil recruitment and IL-8 in the nasal discharge of chronic sinusitis patients. Tohoku J Experimental Medicine 1997; 182: 115-24.
57. Rubin BK, Druce H, Ramirez OE, Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 1997; 155: 2018-23.
58. MacLeod CM, Hamid QA, Cameron L, Tremblay C, Brisco W. Anti-inflammatory activity of clarithromycin in adults with chronically inflamed sinus mucosa. Adv Ther 2001; 18: 75-82.
59. Tsang KW, Ho PI, Chan KN et al. A pilot study of low-dose erythromycin in bronchiectasis. European Respiratory Journal 1999; 13:361-64.
60. Koh YY, Lee MH, Sun YH, Sung KW, Chae JH. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. European Respiratory Journal 1997; 10: 994-99.
61. Nakamura H, Fujishima S, Inoue T et al. Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J 1999; 13: 1371-79.
62. Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 2003; 168: 121-25.
63. Yamanaka A, Saiki S, Tamura S, Saito K. Problems in chronic obstructive bronchial diseases, with special reference to diffuse panbronchiolitis. Naika 1969; 23: 442-51.
64. Homma H, Yamanaka A, Tanimoto S et al. Diffuse panbronchiolitis. A disease of the transitional zone of the lung. Chest 1983; 83: 63-69.
65. Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991; 58: 145-49.
66. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998; 157: 1829-32.
67. Kadota J, Sakito O, Kohno S et al. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1993; 147: 153-59.
68. Ichikawa Y, Ninomiya H, Koga H et al. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am Rev Respir Dis 1992; 146: 196-203.
69. Kadota J, Mukae H, Ishii H et al. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med 2003; 97: 844-50.
70. Fujii T, Kadota J, Morikawa T et al. Inhibitory effect of erythromycin on interleukin 8 production by 1 alpha,25-dihydroxyvitamin D3-stimulated THP-1 cells. Antimicrob Agents Chemother 1996; 40: 1548-51.
71. Mukae H, Kadota J, Kohno S et al. Increase in activated CD8 + cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitis. Am J Respir Crit Care Med 1995; 152: 613-18.
72. Kawakami K, Kadota J, Iida K et al. Phenotypic characterization of T cells in bronchoalveolar lavage fluid (BALF) and peripheral blood of patients with diffuse panbronchiolitis; the importance of cytotoxic T cells. Clin Exp Immunol 1997; 107: 410-16.
73. Yanagihara K, Tomono K, Sawai T et al. Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 1997; 155: 337-42.
74. Jaffe A, Francis J, Rosenthal M, Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998; 351: 420.
75. Pirzada OM, Taylor CJ. Longterm macrolide antibiotics improve pulmonary function in cystic fibrosis (abstract). Pediatr Pulmonol 1999; 28Suppl 19: 263.
76. Anstead MI, Kuhn RJ, Halsay S, Kanga JF. Prolonged benefical effect of chronic azithromycin on lung function in cystic fibrosis (abstract). Pediatr Pulmonol 2000; 30 Suppl 20: 244.
77. Ordonez CL, Stulbarg M, Grundland H, Liu JT, Boushey HA. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. Pediatr Pulmonol 2001; 32: 29-37.
78. Wolter J, Seeney S, Yang IA, Bowler SD, Bell SC, McCormack JG. Azithromycin (AZM) reduces TNF-alpha release from lipopolysaccharide (LPS) - stimulated mononuclear cells (PMBC) in cystic fibrosis (CF) (abstract). Respirology 2000; 5 (Suppl): A53.
79. Wolter JM, Seeney SL, Bowler SD, Masel PJ, Bell SC, McCormack JG. Azithromycin (AZM) in adults with cystic fibrosis (CF) (abstract). Respirology 2001; 6 (Suppl): A5.
80. Molinari G, Paglia P, Schito GC. Inhibition of motility of Pseudomonas aeruginosa and Proteus mirabilis by subinhibitory concentrations of azithromycin. Eur J Clin Microbiol Infect Dis 1992; 11: 469-71.
81. Molinari G, Guzman CA, Pesce A, Schito GC. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother 1993; 31: 681-88.
82. Wozniak DJ, Keyser R. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 2004; 125 (Suppl 2): 62S-69S.
83. Ichimiya T, Takeoka K, Hiramatsu K, Hirai K, Yamasaki T, Nasu M. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy 1996; 42: 186-91.
84. Tateda K, Comte R, Pechere JC, Kohler T, Yamaguchi K, Van Delden C. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001; 45: 1930-33.
85. Saiman L, Chen Y, Gabriel PS, Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2002; 46: 1105-107.
86. Baumann U, Fischer JJ, Gudowius P et al. Buccal adherence of Pseudomonas aeruginosa in patients with cystic fibrosis under long-term therapy with azithromycin. Infection 2001; 29: 7-11.
87. Altschuler EL. Azithromycin, the multidrug-resistant protein, and cystic fibrosis. Lancet 1998; 351: 1286.
88. Pradel P, Delmarco A, Cippolli M, Cazzola G. Chloride transport may be restored by long-term azithromycin treatment in patients with cystic fibrosis (abstract). Pediatr Pulmonol 2000; 30(Suppl 20): 280.
89. Amsden GW. Advanced-generation macrolides: tissue-directed antibiotics. Int J Antimicrob Agents 2001; 18(Suppl 1): S11-15.
90. Wilms EB, Touw DJ, Heijerman HGM. Azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum after chronic administration in CF patients (abstract). Journal of Cystic Fibrosis 2003; 2: S31-S48.
91. Cipolli M, Cazzola G, Novelli A, Cassette M, Fallani S, Mazzei T. Azithromycin Concentrations in Serum and Bronchial Secretions of Patients with Cystic Fibrosis. Clinical Drug Investigation 2001; 21: 353-60.
92. Rubinstein E. Comparative safety of the different macrolides. Int J Antimicrob Agents 2001; 18(Suppl 1): S71-76.
93. Pessayre D. Effects of macrolide antibiotics on drug metabolism in rats and in humans. Int J Clin Pharmacol Res 1983; 3: 449-58.
94. Yasui N, Otani K, Kaneko S, Shimoyama R, Ohkubo T, Sugawara K. Carbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients. Int Clin Psychopharmacol 1997; 12: 225-29.
95. Amsden GW, Cheng KL, Peloquin CA, Nafziger AN. Oral cimetidine prolongs clarithromycin absorption. Antimicrob Agents Chemother 1998; 42: 1578-80.
96. von Rosensteil NA, Adam D. Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf 1995; 13: 105-22.
97. Friedman HS, Bonventre MV Erythromycin-induced digoxin toxicity. Chest 1982; 82: 202.
98. Apseloff G, Foulds G, LaBoy-Goral L, Willavize S, Vincent J. Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers. J Clin Pharmacol 1998; 38: 830-35.
99. Sato RI, Gray DR, Brown SE. Warfarin interaction with erythromycin. Arch Intern Med 1984; 144: 2413-14.
100. Woldtvedt BR, Cahoon CL, Bradley LA, Miller SJ. Possible increased anticoagulation effect of warfarin induced by azithromycin. Ann Pharmacother 1998; 32: 269-70.
101. Fujii T, Kadota J, Kawakami K et al. Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax 1995; 50: 1246-52.
102. Olivier KN, Weber DJ, Wallace RJ, Jr et al. Nontuberculous mycobacteria. 1: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 828-34.